CAS: 261904-39-6; (R)-3-Bromo-2-Hydroxy-2-Methylpropanoic Acid

该化合物是其手性中心特有的有机化合物,有助于其特定的立体化学.该化合物的特点是一个溴原子和一个附属于一个支分支的丙酸脊柱的氢氧基组,使其成为一种溴氢氧酸基,使其成为溴氢氧酸基.该溴原子的存在具有独特的再活性,允许在有机合成和药用化学中进行可能的应用.氢氧基环状体组增强了其在极地溶剂中的溶性,并能够参与氢的结合,影响其物理特性和再活性.作为一种碳盒酸,它表现出酸性的行为,能够捐赠质子溶液.它也可能影响其生物活动,使其对药物研究感兴趣.该化合物的分子结构表明它可能参与各种化学反应,包括替代和化.

结构式图片

相似化合物

106089-20-7 594-61-6 56970-78-6

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号106138-80-1 (3R,8AR)-3-Brom... | CAS号1250440-74-4 (2S,5R)-5-(brom... | CAS号206193-17-1 (R)-3-溴-N-(4-氰基... | CAS号206193-18-2 (2R)-3-溴-2-羟基-2...

合成工艺路线路线简述

    (2R)-1-Methacryloylpyrrolidin-2-Carboxylic Acid置于n-溴代丁二酰亚胺(Nbs),盐酸体系中,用 N,N-二甲基甲酰胺,水 用作溶剂,化学反应生成(2R)-3-溴-2-羟基-2-甲基丙酸
    参考文献: Androgen Receptor Antagonists[fr] Antagonistes Du Récepteur Des Androgènes
    标题: Androgen Receptor Antagonists[fr] Antagonistes Du Récepteur Des Androgènes

    海关参考信息

    专利信息


    专利号:US-7759520-B2
    优先权日:1996-11-27
    标 题 :Synthesis of selective androgen receptor modulators
    发明人:DALTON JAMES T; MILLER DUANE D; YIN DONGHUA; HE YALI
    权利人:UNIV TENNESSEE RES FOUNDATION
    摘要:The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.

    专利号:US-6995284-B2
    优先权日:2000-08-24
    标题 :Synthesis of selective androgen receptor modulators
    发明人:DALTON JAMES T; MILLER DUANE D; HE YALI; YIN DONGHUA
    权利人:UNIV TENNESSEE RES FOUNDATION
    摘要:The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.

    专利号:US-7968721-B2
    优先权日:2003-01-13
    标 题:Large-scale synthesis of selective androgen receptor modulators
    发明人:MILLER DUANE D; VEVERKA KAREN A; CHUNG KIWON
    权利人:UNIV TENNESSEE RES FOUNDATION
    摘要:This invention relates to a process for preparing a selective androgen receptor modulator (SARM) compound represented by the structure of formula I: n nwherein X is O; and T, Z, Y, Q, R and R 1 are defined herein. The process includes coupling between an amide of formula II and a phenol of formula IIIn n n n n n n n n n n nfollowed by a purification step consisting of precipitating the compound of formula (I) in a mixture of alcohol and water alone.

    专利号:US-2004014975-A1
    优先权日:2000-08-24
    标 题:Synthesis of selective androgen receptor modulators

    专利号:US-2006009529-A1
    优先权日:1996-11-27
    标 题:Synthesis of selective androgen receptor modulators

    专利号:ES-2420129-T3
    优先权日:2003-01-13
    标题 :Large-scale synthesis of selective androgen receptor modulators
    天津科创医药中间体技术生产力促进有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.scipharmacn.com
    企业联系电话:022-60116533👤
    📞天津科创医药中间体技术生产力促进有限公司 ⚠️参考联系方式
    联系人:王经理
    电话:022-60116533
    手机:13207668525
    传真:022-60979672
    邮箱:saleskc@scipharmacn.com
    通信地址: 天津市华苑产业园区(环外)海泰发展六道6号海泰绿色产业基地
    邮编: 300118
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:天津市华苑产业园区(环外)海泰发展六道6号海泰绿色产业基地
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1055/a-1845-9291
    摘要:Sani M, Zanda M. Recent Advances in the Synthesis and Medicinal Chemistry of SF5 and SF4Cl Compounds. Synthesis. 2022 Jun 21;54(19):4184–209. doi: 10.1055/a-1845-9291.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知